Skip Navigation

Annals of Oncology 2006 17(8):1181-1183; doi:10.1093/annonc/mdl292
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hupperets, P. S.
Right arrow Articles by Tjan-Heijnen, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hupperets, P. S.
Right arrow Articles by Tjan-Heijnen, V. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

editorial

Primary or secondary G-CSF prophylaxis to support TAC chemotherapy in breast cancer?

P. S. Hupperets1 and V. C. Tjan-Heijnen2,*

1 University Hospital Maastricht, Maastricht, 2 Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

* (E-mail: V.Tjan@onco.umcn.nl)

The first 150 words of the full text of this article appear below.

Taxanes and anthracyclines are two of the most active agents against breast cancer. Many trials with a positive outcome have recently been reported in the adjuvant setting.

In the Cancer and Leukaemia Group B (CALGB) 9344 trial, 3121 women with node-positive breast cancer were randomly assigned to receive a combination of four cycles of AC (doxorubicin 60, 75 or 90 mg/2 and cyclophosphamide), followed by either no further therapy or four cycles of paclitaxel (Taxol) [1Go]. The addition of paclitaxel improved both 5-year disease-free survival (DFS) (70% versus 65%) and overall survival (OS) (80% versus 77%). In the NSABP B-28 trial, with a comparable design in 3060 women with node-positive breast cancer, the addition of paclitaxel resulted in significant improvement in 5-year DFS (76% versus 72%), although no improvement in OS was seen [2Go]. In the BCIRG 001 study, TAC (docetaxel, adriamycin, cyclophosphamide) outperformed classical FAC (5-fluorouracil, adriamycin, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
L.-P. P. Tran and J. L. Grabinski
Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux
Journal of Pharmacy Practice, February 1, 2008; 21(1): 46 - 56.
[Abstract] [PDF]

Home page
 Ann OncolHome page
D. Kerr
Now the New Year reviving old desires
Ann. Onc., January 1, 2007; 18(1): 3 - 3.
[Full Text] [PDF]

Home page
 JCOHome page
T. J. Smith, J. Khatcheressian, and B. Hillner
In Reply
J. Clin. Oncol., December 10, 2006; 24(35): 5616 - 5616.
[Full Text] [PDF]